Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20085563 | 0.82 | TRPA1 (0.46) | NOTUMPTGS1CRHR1LMNATRPA1 | |
| SCHEMBL20085553 | 0.82 | PSEN1 (0.35) | NOTUMPTGS1CRHR1LMNAPSEN1 | |
| SCHEMBL30725597 | 0.81 | KCNH2 (0.43) | NOTUMLMNACNR1 | |
| SCHEMBL16201998 | 0.81 | KCNH2 (0.43) | NOTUMLMNACNR1 | |
| SCHEMBL17720567 | 0.81 | POLB (0.41) | MALT1LMNA | |
| SCHEMBL2921125 | 0.80 | CHRM1 (0.32) | MALT1NOTUMPTGS1CHRM1 | |
| SCHEMBL20085552 | 0.79 | CRHR1 (0.33) | PTGS1CRHR1LMNATRPA1CACNA1C | |
| SCHEMBL6124230 | 0.79 | ALDH1A1 (0.41) | CRHR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21030746 | 0.78 | ALOX5AP (0.36) | CRHR1 | |
| SCHEMBL19814290 | 0.78 | MAPT (0.44) | MALT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190275012-A9 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | LUPIN LIMITED (IN) | 2019-09-12 | — | — | US | disclosed |
| US-20190160045-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | LUPIN LTD (IN) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275012-A9 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | MALT1, PTP4A1, PTPRO | MALT1 1/4885NOTUM 2566/4885PTGS1 933/4885 |
| US-20190160045-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | MALT1, PTP4A1, PTPRO | MALT1 1/4885NOTUM 2566/4885PTGS1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.